<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04727151</url>
  </required_header>
  <id_info>
    <org_study_id>TAC01-HER2-03</org_study_id>
    <nct_id>NCT04727151</nct_id>
  </id_info>
  <brief_title>TAC T-cells for the Treatment of HER2-positive Solid Tumors</brief_title>
  <acronym>TACTIC-2</acronym>
  <official_title>A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Triumvira Immunologics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Triumvira Immunologics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells&#xD;
      expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor&#xD;
      receptor 2 (HER2). TAC directs T-cells to the targeted antigen (HER2), and once engaged with&#xD;
      the target, activates them via the endogenous T cell receptor.&#xD;
&#xD;
      This is an open-label, multicenter Phase 1/2 study that aims to establish safety, Maximum&#xD;
      Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D), pharmacokinetic profile and efficacy&#xD;
      of TAC01-HER2 in subjects with relapsed or refractory solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I: Dose escalation in any 3+ HER2-positive solid tumor.&#xD;
&#xD;
      Phase II: Dose expansion cohorts: 3+ HER2-positive breast cancer (a) and other solid tumors&#xD;
      (b) 2+HER2-positive solid tumors (c).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>24 Months</time_frame>
    <description>Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5 and American Society for Transplantation and Cellular Therapy (ASTCT) 2018 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine MTD or RP2D</measure>
    <time_frame>28-42 Days Post-Treatment</time_frame>
    <description>Assessed by incidence of Dose-Limiting Toxicities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine expansion of TAC01-HER2</measure>
    <time_frame>24 Months</time_frame>
    <description>Assessed by vector copy number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine persistence of TAC01-HER2</measure>
    <time_frame>24 Months</time_frame>
    <description>Assessed by vector copy number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Overall Response Rate (ORR)</measure>
    <time_frame>1, 3, 6, 9, 12, 18 and 24 months</time_frame>
    <description>Assessed by imaging using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Overall Survival (OS)</measure>
    <time_frame>24 Months</time_frame>
    <description>Defined as the time between the date of TAC01-HER2 infusion and death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>HER2-Positive Solid Tumors</condition>
  <arm_group>
    <arm_group_label>TAC01-HER2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lymphodepletion followed by TAC01-HER2 as a single IV infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TAC01-HER2</intervention_name>
    <description>TAC01-HER2, fludarabine, cyclophosphamide.</description>
    <arm_group_label>TAC01-HER2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18 years.&#xD;
&#xD;
          2. A recent tumor sample to confirm HER2-protein expression on tumor cell surface.&#xD;
&#xD;
          3. Relapsed or refractory disease after at least two prior lines of therapy.&#xD;
&#xD;
             a. For breast cancer patients, both prior lines of therapy must include HER2 targeted&#xD;
             agents.&#xD;
&#xD;
          4. Measurable disease per RECIST Version 1.1.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          6. Life expectancy of at least 12 weeks.&#xD;
&#xD;
          7. Adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active inflammatory or neurological disorder, autoimmune disease or infection&#xD;
&#xD;
          2. Acute cardiovascular disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nathan Ternus</last_name>
    <phone>(512) 646-4516</phone>
    <email>patient.info@triumvira.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brooke Pieke, MS</last_name>
      <phone>773-834-9636</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Fadel, BSN, RN</last_name>
      <phone>773-702-4779</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riemke Bouvier</last_name>
      <phone>617-582-9565</phone>
      <email>Riemke_Bouvier@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ecaterina Dumbrava, MD</last_name>
      <phone>713-792-3934</phone>
      <email>eeileana@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Saibil, MD</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>4831</phone_ext>
      <email>Sam.Saibil@uhn.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2-Positive Breast Cancer</keyword>
  <keyword>HER2-Positive Gastric Cancer</keyword>
  <keyword>HER2 Protein Overexpression</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>HER2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

